Which is better, serputinib/serpatinib or platinib?

Selpercatinib and pralsetinib represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers. The therapeutic effects of the two vary depending on individual differences, disease severity and other factors. Which one is better depends on the patient's specific situation and the doctor's advice.

Sepretiniband platinib are two highly selective and potentRET TKIs. Septinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced/metastatic RET-altered medullary thyroid carcinoma (MTC), and papillary thyroid carcinoma, while platinib has been approved by the FDA for the treatment of RET fusion-positive non-small cell lung cancer. The U.S. FDA-approved platinib was updated in 2020 to include advanced/metastatic RET-altered MTC and PTC.

Up to now, the original research drug is sold in China under the name of Seputinib, but it is not included in medical insurance. The price of each box of 80mg*56 tablets may be more than 10,000 yuan. There are European and American versions of the original drugs sold overseas, with the price of each box ranging from 20,000 to more than 100,000 yuan (prices may fluctuate due to exchange rates). Generic drugs of Seputinib have also been put on the market for sale overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*120 capsules produced by a Laos pharmaceutical factory is more than RMB 4,000 per box (the price may fluctuate due to exchange rates).